|
- 积分
- 0
- 威望
- 0
- 包包
- 0
|
Division of Endocrinology-Diabetes-Medical Genetics, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina
% ^$ @3 L0 o" Z; N' _/ n7 k. o0 P5 ^. g+ ^: h$ [* h; M W y
ABSTRACT
5 I1 c; w/ Y8 H) y4 K8 e! V4 ?( L. k0 L7 p, I$ T
In diabetes, mesangial cell proliferation and extracellular matrix expansion are critical components in the development of glomerulosclerosis. We reported that diabetes alters the activity of the kallikrein-kinin system and that these alterations contribute to the development of diabetic nephropathy. The present study examined the influence of streptozotocin-induced diabetes on the renal expression of bradykinin (BK) B2 receptors (B2KR), connective tissue growth factor (CTGF), transforming growth factor- (TGF-), and TGF- type II receptor (TGF-RII) and assessed the signaling mechanisms through which B2KR activation may promote glomerular injury. Eight weeks after the induction of diabetes, renal mRNA levels of B2KR, CTGF, and TGF- as well as protein levels of CTGF and TGF-RII were measured in control (C), diabetic (D), and insulin-treated diabetic (D I) rats. Renal B2KR and TGF- mRNA levels expressed relative to -actin mRNA levels and CTGF and TGF-RII protein levels were significantly increased in D and D I rats compared with C rats (P
8 g* }6 {& \- g* w; b( O
+ r5 Q3 Z2 j2 M% T" Eglomerulosclerosis; diabetic nephropathy; connective tissue growth factor A' T6 a4 C! v0 L! S1 u* E) N
; m" p! E8 Q) m9 O. c# j4 c+ I, ^DIABETIC NEPHROPATHY IS A major cause of morbidity and mortality in diabetes. It is the single most common cause of end-stage renal failure (24, 36). A very characteristic and initial event of the development of diabetic nephropathy is glomerulosclerosis, which is featured by increased thickness of the glomerular basement membrane, and a widening of the mesangium with accumulation of extracellular matrix (ECM). Furthermore, the degree of mesangial expansion is strongly related to the clinical manifestations of diabetic nephropathy, such as albuminuria and decreased glomerular filtration rate (GFR) (7, 29).7 c$ F5 i6 b9 e# p2 T) Y
/ G' w! Z2 O( }1 @- dThe risk factors and pathophysiology for glomerulosclerosis in diabetes are continuing to be defined from clinical and animal models, cellular and subcellular investigations. Although inherent susceptibility seems to influence the rate at which complications develop, the abnormal milieu of the diabetic state (hyperglycemia) is the primary driving force for cellular damage (40). The development of glomerulosclerosis is clearly dependent on hyperglycemia as intensive control of glycemia in type I diabetic patients was associated with a reduction of glomerular lesions (34). High-glucose concentrations induce first proliferation of mesangial cells, followed by the development of hypertrophy, which eventually progress into glomerulosclerosis (3). The initiating and sustaining signals that link hyperglycemia to glomerular sclerosis are not fully realized. Hyperglycemia and its metabolites can directly or indirectly stimulate the synthesis and release of factors from resident renal cells, which in turn can stimulate mesangial cell growth, as well as ECM production in an autocrine or paracrine manner (6, 25). In this regard, the cytokine transforming growth factor (TGF)- has been shown to play a pivotal role in mesangial cell expansion and matrix deposition (33). Recent evidence indicates that the profibrotic signals initiated by TGF- are mediated via activation of connective tissue growth factor (CTGF) (8).7 M. P& _, N( q0 R5 q2 S7 q$ Q
" [0 J5 S/ N7 q9 t/ G' d" k
CTGF was originally identified as a product of human umbilical vein endothelial cells that was both chemotatic and mitogenic for fibroblasts (2). It is now known that CTGF belongs to a new gene family, CCN [named after prototype members of this family CTGF, cyr61, and nov (1)]. The molecular mass of CTGF-like factors varies between 35 and 40 kDa, and the structure of these molecules consists of four modules: an NH2-terminal IGFBP-like domain, a Von Willebrand factor type C repeat domain, a thrombospondin type 1 repeat domain, and a COOH-terminal dimerization domain (1).
5 r- S+ `0 Z2 x4 [ A+ r3 r$ |, k% m7 B' |1 }6 R! `1 }
The biological actions of CTGF are pleiotropic and seem to be cell specific, but the cellular mechanisms of its actions are still undefined. An emerging role of CTGF is that of a prosclerotic factor. Renal expression of CTGF is upregulated by the diabetic state and by other progressive renal diseases (17). In addition, CTGF has been shown to increase collagen I expression in human mesangial cells (10).
2 r" H6 ~, @' y2 A2 e6 q* G: E; E( b2 w- r- S
Accumulating evidence supports a relationship between activity of the kallikrein-kinin system (KKS) and renal impairment. We previously showed that type 1 diabetic patients, at risk for developing nephropathy (those with elevated glomerular hemodynamics), show increased renal kallikrein and kinin production (14). In addition, diabetic rats with moderate hyperglycemia show increased renal and urinary excretion of active kallikrein and kinin, in conjunction with reduced renal vascular resistance (RVR) and increased GFR and renal plasma flow (RPF). Acute treatment of hyperfiltering diabetic rats with aprotinin, a kallikrein inhibitor, or with a B2-kinin receptor antagonist increases the RVR and reduces GFR and RPF (15, 21).
! x9 x4 r- u, |& M9 K* w. M b- N2 `
Although most of the physiological actions of the KKS are attributed to the generation of bradykinin (BK) and activation of B2-kinin receptors, virtually nothing is known about the multiple intracellular signals initiated on activation of BK B2 receptors (B2KR) leading to expression of prosclerotic factors that ultimately result in glomerular injury. Therefore, the present study examined the influence of diabetes on the expression of glomerular B2-kinin receptors and delineated the signal transduction pathway through which B2KR activation promotes the production of CTGF, TGF- type II receptor (TGF-RII), and collagen I in mesangial cells.8 W) ]% O: C. J. Z8 q: p
. J. _4 J; Y8 l* j+ u
METHODS
L; U9 U3 ~8 B6 O8 x
: F2 l) m9 k! N6 }- CInduction of Diabetes: g0 }: W0 C8 W& U
' Z1 S/ i; Q/ |
Male Sprague-Dawley rats (Charles River, Wilmington, MA) weighing 200–220 g were used in all studies. Rats were housed two to three per cage in a light- and temperature-controlled room and had free access to food and water. Diabetes was induced by a single intravenous injection of streptozotocin (STZ), 65 mg/kg body wt through the tail vein. After 24 h, diabetes was confirmed in STZ-treated rats by tail vein plasma glucose levels. Glucose levels and body weights were measured at predetermined intervals to characterize the diabetic state. Age-matched control (C) rats were also studied.2 ?: {# p7 N4 E# h1 T, p
6 B/ ^4 P" L3 \+ N( O7 gThe diabetic rats were divided into two groups. The first group (D) received no insulin treatment and displayed severe hyperglycemia. Plasma glucose levels were 400 mg/dl throughout the 8-wk study period. The second group of diabetic rats (D I) was implanted subcutanousely in the back with insulin capsules that maintained a constant release of insulin (1 U) for 2 mo (Linplant, Linshin, Canada). Insulin therapy began 24 h after induction of diabetes, and plasma glucose levels were maintained in the moderate hyperglycemic range (250 mg/dl) over the 8-wk study period.
' P) b# ] _" `$ W2 b. c* ]6 K
5 H/ J9 v, A- w$ @( D* k- @Mesangial Cell Culture
0 x l1 J! ]8 Y, N4 b
0 G1 a' J9 C( [9 N" I8 PRat glomerular mesangial cells were prepared by a modification of the method of Lovett et al. (26). Glomerular cells collected as described above were incubated in PBS plus 0.1% gentamysin solution and 1% antibiotic antimycotic, pH 7.4, containing collagenase (5 mg/ml), at 37°C for half an hour to remove epithelial cells, leaving the glomerular cores containing mesangial and endothelial cells, vortexed every 10 min during the incubation. The cores were diluted in 1.5 ml RPMI 1640 medium plus HEPES per kidney, containing 0.1% gentamysin solution, 1% antibiotic antimycotic, 0.5% insulin-transferring solution, and 20% FBS, conditions that favor growth of mesangial cells. Cells were incubated at 37°C in a humidified atmosphere of 95% air-5% CO2. Cell viability was assessed by standard dye exclusion techniques, using 0.1% Trypan blue. Mesangial cells were identified by the following criteria. Mesangial cells stained positive for intracellular cytoskeletal fibrils of actin and smooth muscle cell-specific myosin (indicative of contractile cells), desmin, and vimentin and negative for cytokeratin and factor VIII antigens. Morphologically, the mesangial cells had an elongated and stellate or spindle-shaped morphology. Mesangial cells isolated by this procedure were homogenous and were used in all studies between passages 3-8.
4 R! @ y# |# t% W0 I( }% s2 J( |& j8 x
RNA Extraction
' m3 e" d1 \' t: X+ Z; e2 v
' E; t7 J4 X8 |, U9 w& D9 J# G- L0 [( KKidneys from control and diabetic rats were removed under anesthesia and cortexes were isolated to extract RNA using a combined method of TriZOL and RNeasy Midi Kit for total RNA extraction from animal tissue (Qiagen). Briefly, the cortices were homogenized using an appropriate volume of TriZOL (1 ml TriZOL/100 mg tissue). Chloroform (0.2 ml/1 ml TriZOL used) was then added to separate the aqueous phase from protein phase. Total RNA was dissolved in the aqueous phase. The RNA concentration was determined in a spectrophotometer (Ultraspec III, Pharmacia) by absorbance at 260 nm.
) W+ A+ j! ^) {
1 H% Z S/ n1 Z7 R& F* i6 i2 FTotal RNA from mesangial cells was extracted with RNeasy Mini Kit (Qiagen) according to the handbook＊s protocol. The purified RNA was eluted in 30 μl of RNase-free water, and the RNA concentration was determined in a spectrophotometer (Ultraspec III, Pharmacia) by absorbance at 260 nm.
, m# U4 Z8 `/ M# C6 w8 t9 O) ^( a! l; K! p" o: b" |5 t/ R3 c
RT-PCR: S }' O& U! g* i( [2 h8 H
0 q M7 l) b* D% T" D
RNA (2 μg) was converted to cDNA using MLV Reverse Transcriptase (Promega, Madison, WI) according to the manufacturer＊s protocol at 37°C for an hour. In PCR reactions, the following rat primers were used: (TGF-1) 5'-AAG CAC CCG GGT TGT GTT GGT T-3', 3'-GTG ACG AAG GGC TTA CAG ACT G-5'; (collagen I) 5'-AAC GAT GGT GCC AAG GGT GAT-3', 3'-CAA CCA GGA CGA CCG TTC TTA-5'; (CTGF) 5'-CTA AGA CCT GTG GAA TGG GC-3', 3'-CCC CTG TTA CTG TAG AAA CTC-5' (Integrated DNA Technologies). The PCR was performed in 25 μl total volume containing 1x PCR buffer, 200 μM dNTPs, 2 ng/μl primers, 10–80 ng cDNA, and 1 U Taq (Taq DNA polymerase Kit, Qiagen). Reaction condition of TGF-1 was as follows: 95°C for 30 min, 57°C for 45 min, 72°C for 60 min, total 29 cycles. Reaction condition of collagen I was 94°C for 60 min, 60°C for 60 min, 72°C for 60 min, total 30 cycles. Reaction condition of CTGF was 95°C for 45 min, 60°C for 45 min, 72°C for 45 min, total 25 cycles. The PCR products were visualized on a 1% agarose gel, photographs were taken, and the densitometric analysis was performed using the National Institutes of Health (NIH) image program.
7 M6 s; z) J$ M. W/ ?8 w; q1 R* A+ e$ H$ [ C: v
Real-Time PCR
9 C' E d1 g$ m" V2 ~! n, q8 n5 V0 G
Total RNA (2 μg) obtained as described above was converted to cDNA using MLV Reverse Transcriptase (Promega) according to the manufacturer＊s protocol at 37°C for 1 h. To determine the validity of primers and appropriate Tm for real-time PCR, the primers were first amplified in a PCR reaction to ensure that only one band is amplified. The following primers were designed so that all of the PCR products are within 75–150 bp (Integrated DNA Technologies): collagen I, 5'-CAC ACA TCC TGT GTC TCT TCC CAT-3'; 5'-GAT CAA GCA TAC CTC GGG TTT CCA-3'; CTGF 5'-TTT CTG CCC TTG TCA CTC CT-3'; 5'-GTT GGA TAC TCG GGT GGC TA-3'; -actin, 5'-ACT GCC GCA TCC TCT TCC TC-3'; 5'-CCG CTC GTT GCC AAT AGT GA-3'.
: A& G1 H" v6 l$ _0 ]& I4 ?: ?: R7 F7 A: B* l' s
For each target gene, a standard curve was established. This was achieved by performing a series of threefold dilutions of the gene of interest. Negative control was made using the same volume of RNase-free water instead of sample. The master mix was prepared as follows: 2x SYBR Green Supermix (cat. no. 170–8880, Bio-Rad) 12.5 μl, forward and reverse primer 0.25 μl, respectively, and ddH2O 12 μl. For each well, 22 μl of master mix were loaded first, followed by 3 μl of sample, and mixed well to get total reaction volume of 25 μl. For plate setup, SYBR-490 was chosen as fluorophore. The plate was covered with a sheet of optical sealing film. PCR conditions were 95°C for 3 min, followed by 40 cycles of 95°C for 10 s, 58°C for 1 min (for -actin and collagen I), then 95°C for 1 min, 55°C for 1 min, and 100 cycles of 55°C for 10 s. All of the reactions were done in duplicate. The correlation coefficient is between 0.99 and 1; PCR efficiency is between 80 and 120%. The mRNA levels were expressed relative to -actin mRNA. Real-time PCR using iCycle iQ optical system software (version 3.0a) was used in our studies.* U2 }4 S: T* B- ]1 K7 f
% r! ?' A) ?" B6 G& I0 M5 ~Protein Extraction and Western Blot Analysis
6 o( h. Y1 |2 q
/ [0 `8 l$ f. c9 o9 AKidney tissue. Cortices from C, D, and D I rats were minced and homogenized with a polytron for 1 min in 1.5 ml of lysis buffer containing 50 mM Tris﹞HCl, 150 mM NaCl, 0.02% sodium azide, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1 mM PMSF, and protease inhibitor cocktail, pH 8.0. The homogenate was ultracentrifuged for 15 min, and the resultant supernatant was used for measurements of CTGF and TGF-RII and actin protein levels by Western blots.9 h) l3 j5 \- {9 i4 J/ b4 [, P
. {; [; @0 _6 f$ \Cell extracts. Mesangial cells were washed twice, scraped in PBS containing 2 mM sodium vanadate, and centrifuged at 3,000 g for 5 min. Pellets were resuspended in 100 μl of lysis buffer (20 mmol/l Tris, 130 mmol/l NaCl, 10% glycerol, 10 mmol/l CHAPS, 1 mmol/l PMSF, 2 mmol/l Na vanadate, 100 mU/ml aprotinin, 0.156 mg/ml benzamidin, pH 8.0), sonicated for 5 s, incubated on ice for 30 min, and centrifuged at maximum speed for 5 min. The supernatant was used as the protein source and its concentration was determined by the method of Lowry et al. (27).
2 Y) ^ W4 ]2 G' k3 o7 a
" `' D1 p# C. k1 H T7 JWestern Blotting of CTGF and TGF-RII1 o/ w) O& r, C* F8 e
. h$ o' U; o' O* P
Quiescent mesangial cells were stimulated with BK (10–8 M) for 24 h in the presence and absence of either a MAPK inhibitor (PD-98059, 40 μM) and/or the src kinase inhibitor PP1 (10 mM). Soluble protein (20–25 μg) obtained as described above was separated by SDS-PAGE (12%) under reducing conditions and transferred to PVDF membranes using semidry transfer system (20 V, 45 min) and immunoblotted with anti-TGF-RII polyclonal antibody (1:1,000 dilution) and with anti-CTGF polyclonal antibody (1:500 dilution) overnight at 4°C followed by incubating the membranes in a secondary antibody conjugated to horseradish peroxidase (HRP). The immunoreactive bands were visualized using the chemiluminescence reagent Renaissance (New England Nuclear Life Science Products, Boston, MA), according to the procedure described by the supplier. Membranes were exposed to Kodak LS film and bands were measured by densitometry and quantified by NIH image program.9 [$ Q- L# T2 J+ ~ H3 U' T. @+ @
. |$ [1 R. a1 I' Q8 \
MAPK and p60src Kinase Assay5 p5 @# c* V+ C7 ~: Q
$ }' q+ q0 B& A( i9 T7 j
Quiescent mesangial cells stimulated with BK (10–8 M) for 5 min were suspended in 250 μl of lysis buffer (20 mM Tris, 130 mM NaCl, 10% glycerol, 10 mM CHAPS, 1 mM PMSF, 2 mM sodium vanadate, 100 mU/ml aprotinin, 0.15 mg/ml benzamidine, pH 8.0), sonicated for 10 s, and centrifuged at 13,000 g for 10 min. Twenty-five to thirty micrograms of cytosolic fraction were analyzed by SDS-PAGE and the separated proteins were transferred to PVDF membranes and immunoblotted with anti-phospho-MAPK polyclonal antibody (1:3,000 dilution, New England BioLabs, Beverly, MA) and/or anti- phospho-p60src kinase antibody (1:250 dilution). Immunoreactive bands were visualized using the chemiluminescence reagent Renaissance (New England Nuclear Life Science Products), according to the procedure described by the supplier. Membranes were exposed to Kodak LS film and bands were measured by densitometry and quantified by NIH image program.# X7 z7 e) J1 h
. q j( ^9 T( z& n3 xStatistical Analysis% G+ v& h" e3 H6 x; p. @
0 S6 H' @/ \* Q9 C% R( p: T
All data are expressed as means ± SE and were analyzed by ANOVA or Student＊s t-test for unpaired analysis. Values were considered significant if P 4 t. y/ y9 V8 F: {
8 D/ N3 v* P9 A! `' ERESULTS/ A0 u% c7 G3 L# r
3 w6 v( A' x5 R2 B3 @' r
Characteristics of the Diabetic State
# W+ R) F( B7 |4 b ^; g7 n9 k) g) B* V l% Q* \
Plasma glucose levels were markedly elevated the day after STZ injection (402 mg/dl, P 0.05).( V1 A8 B& Z7 z) X+ f0 T
z/ [( q) C8 K& z$ W0 j, k
Upregulation of B2-Kinin Receptors by the Diabetic State
, m! F' [0 O/ T: ^
9 J2 F6 Q+ N6 d [- DThe expression of B2-kinin receptor mRNA levels in the renal cortex of D and D I rats was measured by RT-PCR and compared with levels in C rats. The results shown in Fig. 2 demonstrate that a significant increase in the expression of B2KR was observed in D and D I rats compared with C rats. Diabetes resulted in a 1.71-fold increase in B2KR mRNA levels and insulin-treated diabetic rats resulted in a twofold increase in B2KR mRNA levels, compared with the levels in C rats, P K8 E/ K5 Z) t2 |+ ]
; P4 g6 Q+ [" U2 U$ E
Upregulation of TGF-1 and TGF-RII by Diabetes- ]9 b* `. Y. D5 P5 m6 k
' _8 H! C) F G) B% O0 ]
The renal expression of TGF-1 in C, D, and D I rats was measured by RT-PCR. The results shown in Fig. 3A demonstrate that diabetic as well as insulin-treated diabetic rats resulted in a significant increase in the mRNA levels of TGF- compared with control rats. TGF-1 mRNA levels were not significantly different between D and D I rats. -Actin mRNA levels measured in the same reaction were not different between C, D, and D I rats.6 x" m6 `9 N( k' F/ z
8 z4 }0 s( z2 h, qThe renal protein levels of TGF-RII were also measured in D and D I rats by Western blots and compared with control rats. The results shown in Fig. 3B demonstrate that both D and D I rats produced a twofold significant increase in the protein levels of TGF-RII compared with C rats. This increase in TGF-RII protein levels was not significantly different between D and D I rats.
: l9 D- ~, X; U
3 @3 f3 I A/ P, f5 B" q+ l9 Y( `Regulation of CTGF Expression by the Diabetic State
! }( v" _5 E% M
9 c4 L: X8 p" G2 B9 [Renal CTGF mRNA levels as well as protein levels were measured in C, D, and D I rats. The results in Fig. 4A show that there are no significant differences in CTGF mRNA levels between C, D, and D I rats. However, a significant increase in CTGF protein levels was observed in D and D I rats compared with C rats. CTGF protein levels were increased by about twofold in D rats and by about 1.5-fold in D I rats compared with C rats, P " d* Z5 B' i9 }
. f Q4 g$ X/ f. b8 U8 E9 c& L% J: x
Induction of CTGF and TGF-RII by BK in Mesangial Cells
: n9 E q. K" e& K) u
9 G+ s+ E& d, h" A6 [Studies were initiated to explore whether BK will modulate the expression of CTGF and TGF-RII in mesangial cells. Mesangial cells were stimulated with BK (10–8 M) for 24 h. The protein levels of CTGF and TGF-RII and actin were measured by Western blots using specific anti-CTGF, anti-TGF-RII, and anti-actin antibodies. The results shown in Fig. 5, A and B, represent the intensities of CTGF and TGF-RII protein levels in control and BK-stimulated mesangial cells.% H/ k; A" r' F2 J3 d' h
9 v/ |# c d* M! S
The results demonstrate that BK resulted in a significant increase in the production of CTGF levels and TGF-RII levels compared with unstimulated control cells. These findings provide the first demonstration that BK can induce the expression of CTGF and TGF-RII in mesangial cells.+ L7 q8 w7 Q3 l+ G1 X ?
& d% \$ J/ Y) y9 Q. d/ b: n, s
Activation of MAPK (p42mapk and p44mapk) by BK w# g8 r( o! u8 I! }& H
1 K# U4 b( i, @9 E& oThe MAPK signal transduction pathway represents an important mechanism by which growth factors regulate cell proliferation (32). To assess whether BK activates MAPK, mesangial cells were treated with BK (10–8 M) for 5 min. Cell lysate was analyzed by SDS-PAGE and the separated proteins were transferred to PVDF membranes and immunoblotted with anti-phospho-MAPK antibody (1:4,000 dilution, New England Nuclear BioLabs).
- m' P3 b+ A) \, X9 H) ^- D/ d; s% {8 w
The results shown in Fig. 6 demonstrate that BK increased the tyrosine phosphorylation of p42mapk and p44mapk compared with unstimulated cells (P
, m4 K3 l0 x& H8 H0 y8 M- ^2 L: v8 B) u5 H4 M. R+ n
Activation of p60src Kinase by BK; f1 N) q. C$ l; C. u
+ I2 z. ?/ |+ m7 w
Our findings demonstrate that activation of MAPK in response to BK is inhibited by the src kinase inhibitor PP1. Therefore, to determine whether BK would result in the activation of p60src kinase, mesangial cells were treated with BK (10–8 M) for various times (0, 5, 30, 60 min), and the phosphorylation of p60src was measured by Western blots using anti-phosho src kinase antibodies (1:300 dilution). The results shown in Fig. 7 demonstrate that the tyrosine phosphorylation of p60src was significantly increased by BK with a peak response at 5 min poststimulation.* Y6 Y- W6 M0 j5 l6 a/ ?
, F0 v% d* {) O! e
These findings provide the first evidence that BK stimulates p60src activation and that p60src is upstream of the MAPK pathway.8 E& D" y. O! C+ I2 X+ l
- `# P& a: Q. q: G
Role of MAPK in CTGF and TGF-RII Production in Response to BK
: b8 W* x; g8 V7 V8 M5 r% b% { v5 { u3 i5 l
To examine if MAPK will modulate the expression of CTGF and TGF-RII, mesangial cells were pretreated for 45 min with the MAPK inhibitor (PD-98095), followed by BK (10–8 M) stimulation for 24 h. The protein levels of CTGF and TGF-RII were measured by Western blots. The results shown in Fig. 8, A and B, represent the protein levels of CTGF and TGF-RII expressed as percentage of control.4 H7 h' g* \ Z. v1 U9 s, {' K
& n |8 U' ~ d/ ~$ P
The results demonstrate that the BK once again produced a significant increase in the protein levels of CTGF and TGF-RII compared with unstimulated cells (P ; u( \9 h7 G6 N5 @8 x
+ }3 v& K0 B+ W# x4 h
Role of MAPK and in Collagen I Expression in Response to BK1 v9 x( g3 V) `' i
6 C' `; K9 ^# X; z7 M) ~: R. i) R! uTo examine if MAPK will modulate the expression of collagen I, mesangial cells were pretreated for 45 min with the MAPK inhibitor (PD-98095), followed by BK stimulation for 24 h. The mRNA levels of collagen I were measured by RT-PCR. The results shown in Fig. 9 represent the intensities of collagen I mRNA levels as well as -actin mRNA levels.
% b. I- H8 m1 m' Z- V& b
" h6 Q% \" ]+ v E, H9 E% qThe results demonstrate that the expression of collagen I was undectable in control untreated mesangial cells. However, collagen I mRNA levels were increased dramatically in mesangial cells treated with BK compared with unstimulated control cells. This increase in collagen I mRNA levels induced by BK was completely abolished in the presence of the MAPK inhibitor (PD-98059).* f7 _+ `7 D) t0 w; x
2 y5 k; i" e) o5 O$ V
These findings implicate that the MAPK pathway plays a pivotal role in modulating the expression of collagen I in response to BK in mesangial cells.
' |! Q, `$ e1 V; _
8 n [0 n" `9 c) g0 Q4 u7 JBK-Induced Upregulation of CTGF and Collagen I mRNA Levels Is Mediated Via Activation of B2-Kinin Receptors
" p. H( ?: f9 m/ o. p# v6 C0 R6 E' n. p: c
To determine whether BK stimulates collagen I and CTGF levels via activation of its B2-kinin receptors, mesangial cells were pretreated for 30 min with the B2-kinin receptor antagonist Icatibant (10–6 M) followed with stimulation with BK (10–8 M) for 6 h. Collagen I and CTGF mRNA levels were measured by real-time PCR and expressed relative to -actin mRNA levels. The results shown in Fig. 10 indicate that the addition of Icatibant to mesangial cells significantly reduced the BK-induced upregulation of collagen I and CTGF mRNA levels, demonstrating that BK mediates its effects via activation of B2-kinin receptors.7 ~9 v; q7 ]! a+ T7 V: w# D
3 g3 Q5 R' s+ `, n
DISCUSSION
: y# ?# g2 f3 A; M
6 x- i5 A) F3 G& C' ZThe contribution of the renal KKS to the development of diabetic nephropathy has been the subject of intensive investigation by our research group as well as others (2, 8, 10, 14, 15, 17, 21). We previously showed that the diabetic state is associated with increased expression of glomerular B1- and B2-kinin receptors, abnormal renal prokallikrein synthesis, and activation as well as altered renal and urinary active kallikrein (4, 19). These changes in renal KKS activity were associated with the abnormal renal hemodynamics that are a characteristic manifestation of diabetic nephropathy (14, 15, 21). In the present study, we demonstrate that prolonged duration of diabetes and insulin therapy are associated with increased renal expression of B2KR and of prosclerotic growth factors CTGF, TGF-, and its receptor TGF-RII. Furthermore, our data also demonstrate that activation of B2KR by BK stimulates the expression of CTGF, TGF-RII, and collagen I in mesangial cells. This increase in CTGF, TGF-RII, and collagen I production in response to BK involves activation of scr kinase and the MAPK pathway. These findings provide the first evidence that BK stimulates several key signaling pathways that participate in matrix dysregulation in mesangial cells.
% q/ K- g) z3 ` ~$ w* y. b% y+ Y9 v" M$ k" p6 b' }
The pathogenesis of diabetic nephropathy is multifactorial and involves direct effects of high extracellular glucose concentrations on glomerular, vascular, and tubular function. Metabolic imbalances associated with high tissue glucose levels in the diabetic state may directly influence many signal transduction pathways that contribute to the pathogenesis of diabetic glomerular injury. One of the most appreciated effects of high glucose is the bioactivation of TGF- and the stimulation of ECM protein synthesis (6, 25). Recent evidence indicates that TGF- may mediate its profibrogenic effects via activation of CTGF. The expression of CTGF is induced by TGF- in mesangial cells, indicating that CTGF is a downstream target for TGF- activation (12). Mesangial cells have been shown to induce collagen I and fibronectin expression in response to CTGF stimulation, thus implicating a role for CTGF in matrix deposition and mesangial expansion (10, 39). Furthermore, the glomerular expression of CTGF is induced by experimental diabetes and by high glucose, suggesting that hyperglycemia regulates the expression of CTGF (30, 31). Our data also demonstrate that the renal expression of CTGF, TGF-, and TGF-RII is upregulated in severe hyperglycemic diabetic rats, indicating that hyperglycemia may be the trigger for modulating the expression of CTGF, TGF-, and TGF-RII. Interestingly, we observed that the renal expression of CTGF, TGF-, and TGF-RII in moderately hyperglycemic insulin-treated diabetic rats did not differ significantly from severe hyperglycemic rats, indicating that other factors besides hyperglycemia may contribute to the expression of these genes.- Q" O. F, s4 H$ s7 G
|8 z! l1 S6 f
Our finding of increased expression of renal B2KR supports our previous results showing that glomerular B2KR gene expression is activated within 3 wk after induction of diabetes. However, the present study demonstrates that B2KR expression is maintained at high levels for more prolonged duration of diabetes, suggesting that sustained activation of kinin receptor signaling is necessary to mediate glomerular injury. Although our in vivo data only point to an association between increased expression of B2KR and increased expression of CTGF and TGF-RII, we did however demonstrate that direct activation of B2-kinin receptors by BK results in a marked induction of CTGF, collagen I, and TGF-RII in mesangial cells. In addition, inhibition of B2KR by Icatibant significantly reduced the increase in collagen I and CTGF mRNA levels in response to BK challenge. These findings provide the first evidence that BK can modulate the expression of CTGF, collagen I, and TGF-RII in mesangial cells. Given the functional significance of CTGF and TGF-RII upregulation and their consequences on matrix expression, our data point to a potential mechanistic pathway through which B2KR activation may contribute to mesangial cell expansion in diabetes.
9 I' y, [3 K& ]5 N' X5 ~
2 C2 D* v V7 B+ eAlthough the molecular and cellular signals that promote mesangial expression of CTGF and collagen I in response to diabetes or hyperglycemia are not fully defined, recent findings implicated a pivotal role for the MAPK pathway in this process (13, 16). MAPKs represent a family of serine-threonine kinases that are rapidly activated in response to growth factor stimulation. In mammalian cells, these include ERK1 and ERK2 or p44MAPK and p42MAPK, JNK, and p38MAPK (32). These kinases integrate multiple signal inputs and activated MAPKs are capable of phosphorylating a variety of diverse targets including effector kinases and transcription factors involved in the regulation of genes associated with cellular proliferation and hypertrophy (32). Recent evidence indicates that ligands signaling through G protein-coupled receptors can induce cellular responses that are mediated by activating key effector molecules known to be critical for receptor tyrosine kinase signaling such as src kinase, Ras, Raf, and MAPK (28, 37). This observation, together with the evidence demonstrating that activation of the MAPK cascade is important for receptor tyrosine-mediated growth regulation, suggests that MAPK could be a convergence point for growth signals originating from different G protein-coupled receptors and tyrosine kinase receptors. In this regard, our findings demonstrate that activation of B2KR in response to BK stimulation results in rapid activation of p60src kinase and of p42/p44mapk.6 _! X. L4 [* b% A
" z3 F) z! H" e' A6 I9 m# f9 i
To further delineate the role of cytoplasmic tyrosine kinases in BK-induced p42/p44mapk activation, the effects of cell-permeable-specific inhibitors of src kinase and MAPK kinase were examined. Pretreatment of mesangial cells with the src kinase inhibitor and/or the MAPK kinase inhibitor completely eliminated the increase in p42/p44mapk phosphorylation induced by BK. This finding demonstrates that p42/p44mapk is a downstream target for src kinase and lends further support to our previous results in vascular smooth muscle cells, showing that BK activates p42/p44mapk via p60src kinase, PKC-, and MAPK kinase (37).
, o3 w3 t5 q2 G" y0 N8 ? c/ U1 m
7 D; j. w0 F0 |+ mThe initiating and sustaining signals that link B2KR activation to CTGF, TGF-RII, and collagen I expression in mesangial cells are still not fully defined. In the present study, we provide evidence that the activation of p42/p44mapk by BK is critical for the production of CTGF, TGF-RII, and collagen I. Pretreatment of mesangial cells with the MAPK kinase inhibitor PD-98059 prevented the BK-induced increase in CTGF and TGF-RII protein levels and the increase in collagen I mRNA levels. One possible mechanism through which p42/p44mapk may modulate BK-induced gene expression is via transcriptional activation of the AP-1 complex. We previously showed that BK can promote nuclear translocation of p42/p44mapk and can induce the expression of protooncogenes c-fos and c-jun and the formation of AP-1 complex transcription factor (20). The increase in c-fos mRNA levels and the formation of AP-1 complex in response to BK were mediated via activation of p42/p44mapk (9, 11). The promoter regions of collagen I gene and the TGF- gene have been shown to be regulated by transcription factors such as AP-1 (5, 23). Therefore, one can speculate that activation of B2KR by BK in mesangial cells results in activation and nuclear translocation of p42/p44mapk, leading to the formation of the transcription factor AP-1, which leads to transcriptional activation of TGF- gene and collagen I gene. Alternatively, once expression of TGF- gene is induced by BK it can directly stimulate the expression of CTGF and collagen I. Thus interventional strategies aimed at the level of B2KR inhibition may be a useful approach to prevent this cascade of intracellular events that eventually result in mesangial cell expansion as a result of matrix deposition, a hallmark feature of diabetic nephropathy.
0 _& V: I; O9 t( Q8 ]$ u) b) S
4 C: W" `/ B' k* _GRANTS0 q1 ?7 R/ p6 v9 W
% B% h3 M9 h) Y5 D9 t3 C+ _- h! j3 d4 l
This work was supported by National Institutes of Health Grants DK-46543 and HL-55782 and the American Society of Nephrology (A. A. Jaffa). e# E. o0 U( x5 p# E. U
" ]9 I( G3 n% tFOOTNOTES
" [' p% @% e* u4 T+ i* v6 Y. A) ~# C9 ?) b
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact." K( H$ I& h( i" \' W7 M u( _
/ o8 o7 h0 k% p/ ^
REFERENCES3 n8 D' o: t; G/ q
$ T* A, U$ ]( b" g5 ]2 q$ NBork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 327: 125–130, 1993.
7 C, E c; \3 `' [$ ^9 Y* y. ?: I& W& ~
Bradham DM, Igarashi A, Potter RL, and Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 114: 1285–1294, 1991.
2 Y$ e* F7 z3 j) x' u, i( h: _( Z0 m- k7 k
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820, 2001.
0 s" c% f0 h. u; w% f' p( w8 J
' z: e/ r6 D% N2 Y/ z" O9 OChristopher J and Jaffa AA. Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol 2: 1771–1779, 2002.- V; B9 L$ F+ n7 F7 f
) p0 j% p2 c4 wChung KY, Agarwal A, Uitto J, and Mauviel A. An AP-1 binding sequence is essential for regulation of the human 2 (I) collagen (COL1A2) promoter activity by transforming growth factor-. J Biol Chem 271: 3272–3278, 1996.
" U! u% j6 z* s: h/ X! y+ U: k" D, l) \! I6 [
DeRubertis FR and Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms of potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 43: 1–8, 1994.
, E6 p4 \. |$ Z# h6 Y0 o4 T F* i
* I* V; V, [5 Y" C4 pDrummond K and Mauer M, for the International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes: early renal structural changes in type 1 diabetes. Diabetes 51: 1580–1587, 2002.. b, T' U2 U7 x# Y( V! \5 c+ f
3 w; U h L0 w3 ?. ^
Duncan MR, Frazier KS, Abramson S, Williams S, Kalpper H, Huang X, and Grotendorst GR. Connective tissue growth factor mediates transforming growth factor--induced collagen synthesis: downregulation by cAMP. FASEB J 13: 1774–1786, 1999.
; Z/ l; z c; j( v2 j0 n7 D/ e0 s4 y* b
El-Dahr SS, Dipp S, and Baricos WH. Bradykinin stimulates the ERK-ELK-1-Fos/AP-1 pathway in mesangial cells. Am J Physiol Renal Physiol 275: F343–F352, 1998.; @/ \ b' C; O- \
0 W6 ]0 |$ z2 ]$ [
Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Hazen-Martin D, Greene EL, Grorendorst G, and Trojanowska M. TGF- and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 283: F707–F716, 2002.$ h }8 f v* U0 E3 m) Y* O
( q" K# A4 H* `& y
Greene EL, Velarde V, and Jaffa AA. Role of reactive oxygen species in bradykinin-induced mitogen activated protein kinase and c-fos induction in vascular cells. Hypertension 35: 942–947, 2000.
8 R6 E" Z0 H( q/ P) m0 T6 n# L/ R; l8 l
Grotendorst GR, Okochi H, and Hayashi N. A novel transforming growth factor- response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 7: 469–480, 1996.
! d/ D( m" S3 p. I, U2 ~0 M4 d! F) h! N
Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, and Kikkawa R. MAPK cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 46: 847–853, 1997.
0 R3 e t) X6 N! `) Q% F' J! g( ]* s2 ~0 ~) M/ s5 }
Harvey JN, Edmundson AW, Jaffa AA, Martin LL, and Mayfield RK. Renal kallikrein excretion of kallikrein and eicosanoids in patients with type 1 diabetes: relationship to glomerular and tubular function. Diabetologia 35: 857–862, 1992.2 H* B. x# e3 u2 J
1 F) x) Y" V, T ]
Harvey JN, Jaffa AA, Margolius HS, and Mayfield RK. Renal kallikrein and the hemodynamic abnormalities of the diabetic kidney. Diabetes 39: 299–304, 1990.6 X4 \: n% L; @4 c/ L
" c0 y! ?; f5 |Isono M, Cruz C, Chen S, Hong S, and Ziyadeh FN. Extracellular signal-regulated kinase mediates stimulation of TGF- and matrix by high glucose in mesangial cells. J Am Soc Nephrol 11: 2222–2230, 2000.- |; J9 A6 f8 Y
! Y% B& [ x2 ^
Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, and Goldschmeding R. Expression of connective tissue growth factor in renal fibrosis. Kidney Int 53: 853–861, 1998.
2 A5 o! P2 B' _+ b
) E+ k- f1 Y5 HJaffa AA, Chai KX, Chao J, Chao L, and Mayfield RK. Effects of diabetes and insulin on expression of kallikrein and rennin genes in the kidney. Kidney Int 47: 789–795, 1992.8 k4 E! v) r/ }! N2 X$ u. n
5 p% j2 f' g1 N: \7 Z$ X3 F
Jaffa AA, Miller DH, Bailey GS, Chao J, Margolius HS, and Mayfield RK. Abnormal regulation of renal kallikrein in experimental diabetes: effects of insulin on prokallikrein synthesis and activation. J Clin Invest 80: 1651–1659, 1987.
+ S1 @/ R6 [8 z* k% Z8 `5 g1 l
+ ]- ^7 O6 u' NJaffa AA, Miller BS, Rosenzweig SA, Naidu PS, Velarde V, and Mayfield RK. Bradykinin induces tubulin phosphorylation and nuclear translocation of MAP kinase in mesangial cells. Am J Physiol Renal Physiol 273: F916–F924, 1997.3 ]6 a" |, H7 H+ R' O' u" Y5 a
0 i- y4 Y" q. i# Z( P6 U, c
Jaffa AA, Rust PF, and Mayfield RK. Kinin: a mediator of diabetes-induced glomerular hyperfiltration. Diabetes 44: 156–160, 1995.
7 H- x2 u$ F7 C* E7 h, P; L
( V% l- J0 E7 lJaffa AA, Vio CP, Velarde V, LeRoith D, and Mayfiled RK. Renal kallikrein and renin mRNA levels in diabetes and their induction by insulin and insulin-like growth factor I. Diabetes 46: 2040–2056, 1997." V- P$ L1 P9 Q
) X8 q4 t9 Z/ O( d
Kim S, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, and Roberts AB. Autoinduction of transforming growth factor- is mediated by the AP-1 complex. Mol Cell Biol 10: 1492–1497, 1990.
0 }! M, l, Z0 [9 ~. |; w, |& l* V! H$ R- c4 K6 `
Klahr S, Schreiner G, and Ichikawa I. The progression of renal disease. N Engl J Med 318: 1657–1666, 1988.
% C1 m7 _$ J+ }3 M V: e$ A f, i2 ^: U& f8 {) `4 |6 b
Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, and King GL. Characterization of PKC isoform activation on gene expression of transforming growth factor-, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100: 115–126, 1997.3 b! L" n0 l- \$ p, U2 W- u: n
, j; w* i3 f! ^$ I7 d2 ]2 I; U
Lovett DH, Sterzel RB, Kashgarian M, and Ryan JL. Proteinase activity produced in vitro by cells of glomerular mesangium. Kidney Int 23: 342–349, 1983.: i0 z' N( b8 |- C# N, [7 i' C0 N
e8 D6 S5 @ a1 a$ A$ N' eLowry OH, Rosenbrough NJ, Faee AL, and Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275, 1957.6 c% \* Q' E b( i; a6 R0 @
8 a7 D- }6 ]! s6 f6 u3 G
Lutterel LM, Hawes BE, Biesen TV, Lutterel DK, Lansing TJ, and Lefkowitz RJ. Role of c-src tyrosine kinases in G protein-coupled receptor G subunit-mediated activation of mitogen activated protein kinases. J Biol Chem 271: 19443–19450, 1996.3 H- X/ @5 v% e6 o! ^- ~
E$ D% R/ @" FMauer M and Drummond K, for the International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes: study design and baseline characteristics of the study participants. Diabetes 51: 1572–1579, 2000.
- ~# `. b5 @5 b/ D9 c0 u1 L, o3 y+ r9 k
Murphy M, Godson C, Cannon S, Kato S, Machenzie HS, Martin F, and Brady HR. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274: 5830–5834, 1999.5 [* W8 `" P! } i* G
9 o# h/ `- n: w
Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, and Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11: 25–38, 2000.. p3 \8 r9 K. x3 n
) f* M, X6 y+ [* k/ E* fSchaeffer HJ and Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435–2444, 1999.
; G& y% Q: W1 E5 c" h9 I
7 S% z l5 e6 |9 ?Sharma K and Ziyadeh FN. The emerging role of transforming growth factor- in kidney disease. Am J Physiol Renal Fluid Electrolyte Physiol 266: F829–F842, 1994.5 N' ^0 f- d* u3 S9 I3 y
1 E6 n4 F! C1 _! X$ k! jThe Diabetes Control and Complications Research Study Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47: 1703–1720, 1995.8 c% t! c8 e& U2 w: m9 V( ~8 A6 o
' E! p/ h2 p( H- p& z) L
Tschope CA, Reinecke A, Seidl U, Yu M, Gavriluk V, Riester U, Gohlke P, Graf K, Bader M, Hilgenfeldt U, Pesquero JB, Ritz E, and Unger T. Functional, biochemical and molecular investigations of renal kallikrein-kinin system in diabetic rats. Am J Physiol Heart Circ Physiol 277: H2333–H2340, 1999., F& i: V$ J. c4 l1 J- Z) g
9 z) H' U2 M+ @: `" Z
United States Renal Data System. 2000 Annual Data Report. Bethesda, MD: National Institutes of Health, 2000.5 b P# D/ u/ w N2 m
- s+ ~* J& s4 bVelarde V, Ullian ME, Morinelli TA, Mayfield RK, and Jaffa AA. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am J Physiol Cell Physiol 277: C253–C261, 1999.
, x Z! |) D5 p; G9 ?2 y& _0 D/ l7 J& T9 A5 L9 i1 X8 ^* a# O0 v
Vora JP, Oyama TT, Thompson MM, and Anderson S. Interactions of the kallikrein-kinin system and renin-angiotensin systems in experimental diabetes. Diabetes 46: 107–112, 1997.
5 C% ]+ r" p8 h+ S! Q$ M+ `. c7 g. h, ^/ `% I( [$ D+ M ^
Weston BS, Wahab NA, and Mason RM. CTGF mediates TGF--induced fibronectin matrix deposition by upregulating active 51-integrin in human mesangial cells. J Am Soc Nephrol 14: 601–610, 2003.$ E0 N: l4 T0 K
8 q2 g8 l( k& l+ `' [! h |' F0 n: _
Wolf G and Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56: 393–405, 1999.(Yan Tan, Bing Wang, Joo-S) |
|
发表于 2009-4-21 13:05
